ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study.

Citation data:

PloS one, ISSN: 1932-6203, Vol: 2, Issue: 3, Page: e289

Publication Year:
Usage 5455
Full Text Views 5382
Downloads 39
Abstract Views 19
Views 15
Captures 14
Exports-Saves 13
Readers 1
Citations 13
Citation Indexes 13
Repository URL:;
10.1371/journal.pone.0000289; 10.1371/journal.pone.0000289.t003; 10.1371/journal.pone.0000289.t005; 10.1371/journal.pone.0000289.g002; 10.1371/journal.pone.0000289.t004; 10.1371/journal.pone.0000289.t002; 10.1371/journal.pone.0000289.t001; 10.1371/journal.pone.0000289.g001
PMC1808432; 1808432
Jill M. Ferdinands; David M. Mannino; Marta L. Gwinn; Molly S. Bray; Florian Kronenberg
Public Library of Science (PLoS); Figshare
Agricultural and Biological Sciences; Biochemistry, Genetics and Molecular Biology; Medicine; Amino Acid Substitution; Atherosclerosis; Cohort Studies; Female; Follow-Up Studies; Humans; Lung; Male; Middle Aged; Mutation; Missense; Polymorphism; Genetic; Probability; Receptors; Adrenergic; beta-2; Respiratory Function Tests; Risk Factors; Smoking; United States; Infectious Diseases; Genetics; Biotechnology; adjusted; ratios; baseline; beta-agonist; genetics and genomics; public health and epidemiology; respiratory medicine; respiratory medicine/asthma; Cancer; arg16gly; results; atherosclerosis; communities; genotypic; genotype; subjects; deaths; follow-up; 110309 Infectious Diseases; Medicine and Health Sciences
article media
article description
Growing evidence suggests that the Arg16Arg genotype of the beta-2 adrenergic receptor gene may be associated with adverse effects of beta-agonist therapy. We sought to examine the association of beta-agonist use and the Arg16Gly polymorphism with lung function and mortality among participants in the Atherosclerosis Risk in Communities study.